Peer Education on HPV: Impact on Health Sciences Students' Knowledge, Awareness, and Concern

March 27, 2025 updated by: Beyzanur İşbay Aydemir, Saglik Bilimleri Universitesi

The Effect of Peer Education for Human Papilloma Virus (HPV) on Knowledge, Awareness and Concern Levels of Students in the Faculty of Health Sciences

According to the World Health Organization (WHO), 400 million treatable sexually transmitted diseases (STDs) such as syphilis, chlamydia and human papillomavirus (HPV) occur each year in people aged 15-49, mostly in developing countries. As HPV is a sexually transmitted virus, it has been shown to be the most important aetiological factor in cervical cancer in women (99.7%). Vaccination and education of young people about sexuality and STDs are very important in the prevention of HPV. In this respect, the aim of this study was to find out the level of knowledge, concern and awareness of HPV infection among university students and to increase their awareness by informing them about the subject through their peers. The study was conducted as a pre-test and post-test one-group study. The sample of the study consisted of all final year students of Physiotherapy and Rehabilitation (85 students), Nutrition and Dietetics (60 students), Audiology (35 students), Child Development (80 students), Health Management (44 students) and Social Work (45 students) studying in the spring semester of the 2023-2024 academic year. The students were trained by the Gynaecology Nursing Intern student group (9 students) of the Department of Nursing. Data were collected using the Sociodemographic Characteristics Form, the HPV Knowledge Scale and the Human Papilloma Virus Awareness and Concern Level Scale (HPV-FAS). The relevant forms and the consent form were completed by the students before, after and one month after the training.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Completed

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
127

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Turkey
    • Türkiye
      • İstanbul, Türkiye, Turkey
        • Istanbul Aydın University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • All individuals who are senior students in the Faculty of Health Sciences departments and who agree to participate in the study will be included in the study.

Exclusion Criteria:

  • Individuals who did not complete the study and did not speak and understand Turkish were excluded from the study.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: Sleep Hygiene Training
Behavioral: peer education
The training titled "The Effect of Peer Education on Human Papillomavirus (HPV) for Students in the Faculty of Health Sciences on Knowledge, Awareness, and Concern Levels" includes scientific and up-to-date information about HPV transmission methods, prevention, risk factors, treatment methods, and vaccination. The content of the training aims to provide students with accurate information about HPV, as well as highlight the negative health effects of the virus, particularly its association with serious diseases like cervical cancer. The training seeks to increase students' awareness of HPV and help them manage their levels of concern about the virus. Through the peer education method, students were able to interact with each other, thus providing a more effective learning experience.

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Sociodemographic Characteristics Form
Time Frame: Through study completion, an average of 6 months
It consists of nine questions containing sociodemographic data of students, developed by the researchers.
Through study completion, an average of 6 months
HPV Knowledge Scale (HPV-KS)
Time Frame: Through study completion, an average of 6 months
The HPV-KS was developed in 2013 by Waller and colleagues to measure individuals' knowledge levels about HPV, the HPV vaccine, and screening tests. The scale examines whether individuals have previously heard about HPV, the HPV vaccine, and HPV screening tests, as well as the extent of their knowledge on these topics. The first subdimension of the HPV-KS consists of 16 items and assesses participants' general knowledge about HPV. The second subdimension includes six items and is related to HPV screening tests. The third subdimension consists of seven items and asks participants to respond to items about the HPV vaccine. The independent subdimension of the HPV-KS has been developed in three different forms for the HPV vaccination program conducted in three different countries. For each item in the HPV-KS, participants are expected to mark "Yes," "No," or "I don't know." The total score obtained from the HPV-KS ranges from 0 to 33.
Through study completion, an average of 6 months
Human Papillomavirus Awareness and Concern Scale (HPV-ACS)
Time Frame: Through study completion, an average of 6 months
Developed by Yılmaz Esencan and colleagues (2023), this scale is designed as a five-point Likert-type and consists of 19 items and three subdimensions. The subdimensions of the scale are "Concern about health," "Concern about being excluded," and "Awareness." The scale scores range from a minimum of 0 to a maximum of 76 points. A higher total score indicates a stronger awareness of HPV. The Cronbach's Alpha reliability coefficient of the original scale was determined to be 0.905.
Through study completion, an average of 6 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Saglik Bilimleri Universitesi

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
May 1, 2024

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
June 15, 2024

Study Completion (Actual)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
March 15, 2025

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
March 27, 2025

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
March 27, 2025

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
April 3, 2025

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
April 3, 2025

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
March 27, 2025

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
March 1, 2025

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • 2024/04

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings